AER002 for COVID-19: real-time analysis

Download Image

Post

c19early.org

AER002 for COVID-19

1 study with 36 patients

No significant improvements are seen in meta-analysis to date.

COVID-19 AER002 studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−6%

RCTs (1)−6%

Late (1)−6%

00.511.5+

← AER002
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}


Oct 28 2025	Peluso et al., medRxiv, doi:10.64898/2026.03.07.26347857 (results released 10/28/25)	A phase 2a double-blind, placebo-controlled randomized trial of the SARS-CoV-2-specific monoclonal antibody AER002 in people with Long COVID
Oct 28 2025	6% higher long COVID (p=0.25). RCT 36 long COVID outpatients showing no significant clinical benefit with the AER002 monoclonal antibody compared to placebo.